Vir Bio Reports Q3 2026 Financial Results and Gilead Collaboration Details
Vir Bio (VIR) reported its third-quarter 2026 financial results, highlighting a significant narrowing of net losses to $96.3 million ($0.57 per share) compared to $163.1 million in the prior year period. The company maintains a strong liquidity position with $901.3 million in cash and investments as of September 30, 2026, providing an operational runway into the second half of 2028. Key strategic developments include a collaboration with Gilead Sciences involving up to $1.74 billion in potential milestone payments and tiered royalties on solid tumor candidates. Clinical progress remains central to the company's outlook, with top-line data from the ECLIPSE-1 trial expected in Q4 2026 and Phase III studies for VIR-5500 planned for 2027.
Topics: cash runway clinical trial data timeline collaboration agreement earnings report
Read the full article at Motley Fool
Part of the story Vir Bio Reports Q3 2026 Financial Results and Gilead Collaboration Details (2 articles)